Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Jeff Chan who wrote (217)	1/27/2000 12:56:00 PM
From: thebeach	Read Replies (1) \| Respond to of 356

NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS FOR: PROCYON BIOPHARMA INC. CDNX SYMBOL: PBP JANUARY 27, 2000 Procyon Announces Board Changes: Dr. Bernard Coupal Joins Board of Procyon BioPharma MONTREAL, QUEBEC--Procyon BioPharma Inc.("Procyon") announces the appointment to its Board of Dr. Bernard Coupal, President of T2C2, representing the Societe Innovatech du Grand Montreal. "I am pleased and honored that a person of Dr. Coupal's stature, a key figure in Quebec's financial and biotechnology communities, has agreed to join our board and add his expertise to assist in Procyon's development," stated Mr. Hans J. Mader, Procyon's President and CEO. Before joining T2C2, Dr. Coupal acted as President and General Manager of the Societe Innovatech du Grand Montreal, a company he created in 1992 after taking part in the creation of BioCapital, a venture capital company in the biotechnology sector. Earlier he was the first Director-General of the National Research Council of Canada's Biotechnology Research Institute and assumed various management positions with companies specializing in new technologies. At the same time, Mr. William R. McMahan, President and CEO of Oxbow Equities Corp., will be leaving the Board due to other commitments. "I want to thank Mr. McMahan for his excellent contribution to Procyon during his tenure and I wish him the best in his future endeavors," said Mr. Mader. "Procyon has reached a very important stage in its development with two near-term products approaching commercialization and intensive R&D efforts on its two core technologies. The quality of this Board with its excellent balance of scientific and business expertise obtained both in Europe and North America, provides the Company with a strong foundation of expert counsel," Mr. Mader added. /T/ Procyon Biopharma's Board of Directors Below is a list of the other members of the Board of Procyon Biopharma: * James Youmans, Chairman of the Board of Procyon and former COO of Novartis International in Switzerland: over 25 years experience in the international pharmaceutical industry. * Dr. Phil Gold, Executive Director, Clinical Research Centre, Montreal General Hospital - McGill University Health Center: 30 years experience in clinical medicine and research and an acknowledged expert in the field of oncology. * Charles Bernie (Bud) Johnston, Jr.: former Dean of the Ivey School of Business at the University of Western Ontario: vast business management experience; * Dr. Max Link, former Chairman and CEO of Sandoz Pharma Ltd. and the former CEO of Corange, Ltd.: strong North American and European experience in biotechnology and pharmaceuticals; * William MacDonald Jr., Vice-President, Investments and Portfolio Management, Dolmac Holdings Ltd.: extensive American business experience; * lain Maclnnes, co-founder of Procyon Biopharma and Vice President with National Bank Financial; * Hans J. Mader, President and CEO, Procyon Biopharma: broad North American and European management experience in the pharmaceutical industry. * Dr. Chandra J. Panchal, Executive Vice-President and co-founder of Procyon Biopharma: enormous experience in scientific research and development; /T/ Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. Procyon also has two late-stage products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the CDNX under the ticker symbol, PBP. The CDNX has neither approved or disapproved the information contained in this release.